Show simple item record

dc.creatorMahmud-Al-Rafat, Abdullah
dc.creatorHaque Asim, Muzammal
dc.creatorTaylor-Robinson, Andrew W.
dc.creatorMajumder, Apurba
dc.creatorMuktadir, Abdul
dc.creatorMuktadir, Hasneen
dc.creatorKarim, Mahbubul
dc.creatorKhan, Imran
dc.creatorMainul Ahasan, Mohammad
dc.creatorBillah, Morsaline
dc.date.accessioned2020-09-02T17:54:53Z
dc.date.available2020-09-02T17:54:53Z
dc.date.created2020
dc.identifier.issn1043-4666spa
dc.identifier.otherhttps://doi.org/10.1016/j.cyto.2020.155228spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/12617
dc.description.abstractThe COVID-19 pandemic has led to twin public health and economic crises around the world. Not only has it cost hundreds of thousands of lives but also severely impacted livelihoods and placed enormous strain on community healthcare and welfare services. In this review, we explore the events associated with SARS-CoV-2 pathogenesis and host immunopathological reactivity due to the clinical manifestations of this coronavirus infection. We discuss that the metallopeptidase enzyme ADAM17, also known as tumor necrosis factor-α-converting enzyme, TACE, is responsible for shedding of angiotensin-converting enzyme 2 and membrane-bound interleukin (IL)-6 receptor. This leads to elevated pro-inflammatory responses that result in cytokine storm syndrome. We argue that cytokine balance may be restored by recovering an IL-6 trans-signaling neutralizing buffer system through the mediation of recombinant soluble glycoprotein 130 and recombinant ADAM17/TACE prodomain inhibitor. This cytokine restoration, possibly combined with inhibition of SARS-CoV-2 entry as well as replication and coagulopathy, could be introduced as a novel approach to treat patients with severe COVID-19. In cases of co-morbidity, therapies related to the management of associated disease conditions could ameliorate those clinical manifestations.spa
dc.format.extent31 páginasspa
dc.format.mimetypeimage/jepgspa
dc.language.isoengspa
dc.publisherCytokinespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectSARS-CoV-2spa
dc.subjectIL-6spa
dc.subjectADAM17spa
dc.subjectTACEspa
dc.subjectADAM17/TACE inhibitorspa
dc.subjectSgp130Fcspa
dc.subjectTherapyspa
dc.titleA combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 casesspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.identifier.doihttps://doi.org/10.1016/j.cyto.2020.155228spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record